الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
This study included 60 consecutive patients, [42 males (70%), 18 females (30%), with a mean age of 56.2±6.2 years, with a diagnosis of acute STEMI and successfully treated by thrombolytic therapy (Streptokinase) at CCUs of Minia University Hospital and Minia Health Insurance Hospital in the period from June 2014 to June 2015.
The serum TN-C levels were measured from blood samples withdrawn at 5th to 7th day from admission. Follow up of our patients was by 6th month post STEMI for investigating endpoints of major adverse cardiac events (MACE) and left ventricular (LV) remodeling.
Twenty age and gender – matched apparently healthy subjects were included as controls, [14 males (70%), 6 females (30%), with a mean age of 53±7.4 years].
Patients were classified according to occurrence of LV remodeling into 2 groups, group 1 Remodeling group and group 2 non-Remodeling group.
There was no statistical significant difference between patients and controls regarding basic EDV. Meanwhile; TN-C was significantly higher in patients compared to controls (57.5±19.9 vs. 34.1±3.2 ng/ml, p<0.0001).
There was no statistical significant difference between both groups regarding age, gender, hypertension, smoking, infarct site, basic EDV, Troponin-I level and MACE. While; LV Remodeling group included more diabetic patients (38% Vs. 5%, p=0.001). CKmb, TN-C were significantly higher in LV Remodeling group (80.3± 19.9 vs. 47.6±9.5 ng/ml, p=0.002).
LV remodeling had significant positive correlation with DM, high CKmb and TN-C levels. Moreover; MACE had significant positive correlation with DM and high TN-C.
Multivariate regression analysis for the risk factors correlated with LV remodeling, showed that TN-C was the most independent predictor for LV remodeling.
ROC analysis revealed that TN–C level ≥ 68.9 ng/ml can predict LV remodeling by sensitivity of 81% and specificity of 95% (AUC=0.872).
Thus, we recommend assessment of serum TN-C levels in acute stages following AMI, as it may be a predictive biomarker of LV remodeling during the recovery phase and prognosis.